Gland Pharma names Shyamakant Giri as new CEO
New Delhi: Gland Pharma has announced a major leadership change with the appointment of Shyamakant Giri as the new Chief Executive Officer (CEO), effective January 15, 2025. The appointment, approved by the Board and recommended by the Nomination and Remuneration Committee, aims to drive the company’s next phase of growth.
Shyamakant Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in leading Indian and multinational organizations across Asia, Africa, MENA & LATAM markets. He possesses experience in creating new ventures and improving existing businesses, developing leaders, identifying opportunities for value creation, and executing with discipline. His specialties include Business Development, Operations, Strategy, Product Marketing, start-ups, and turnarounds.
Giri is currently serving as the President (India Business & Emerging Markets) of Amneal Pharmaceuticals, responsible for the commercial expansion and growth in India and Rest of the World markets. Previously, Giri was associated with Rivaara Labs as the Chief Executive Officer. Earlier, Giri was associated in various roles with Abbott India, AbbVie (India Region) and Abbott Diagnostics for almost eighteen years (2002-2020). Mr. Giri started his professional career with Wockhardt Ltd. and was associated during the period 1999-2002.
Giri has done his Master’s in Marketing Management from Jamnalal Bajaj Institute of Management Studies and also holds a Master’s degree in Science (Organic Chemistry) from Mumbai University. He completed his Executive Programme from INSEAD, Singapore and Executive Programme in Hospital Management from Indian Institute of Management, Ahmedabad.
Consequent to appointment of new CEO of the Company, Srinivas Sadu shall continue to be the Executive Chairman of the Company effective January 15, 2025. Srinivas Sadu has been a Director on the Board since April 25, 2019. Srinivas Sadu is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.
Next Story
